Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of ($0.92), $0.01 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $1.42 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.